Form 4: Olema Pharma Executive Sells Shares, Updates Holdings

Olema Pharmaceuticals' Chief Discovery Officer, David C. Myles, reported multiple sales and a gift of common stock, alongside an update to his beneficial ownership.

Summary

• David C. Myles, Chief Discovery & Non-Clinical Development Officer of Olema Pharmaceuticals, Inc., reported several transactions involving the company's common stock on December 19, 2025.
• Myles sold 1,225 shares at a weighted average price of $28.08 per share, with prices ranging from $28.075 to $28.130.
• An additional 43,729 shares were sold at a weighted average price of $30.40 per share, with prices ranging from $30.00 to $30.995.
• A further 6,046 shares were sold at a weighted average price of $31.39 per share, with prices ranging from $31.00 to $31.595.
• Myles also gifted 9,000 shares of common stock on December 19, 2025, at a price of $0.
• Following these transactions, Myles directly beneficially owns 542,881 shares of common stock.
• Indirect beneficial ownership includes 12,831 shares held by The Myles Family Revocable Inter Vivos Trust and 154,846 shares held by Myles Properties Inc.
• The filing corrected a scrivener's error from a December 11, 2024, Form 4, which had understated direct beneficial ownership by 60 shares.
• The reported direct beneficial ownership also includes 4,488 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025.

Sentiment

Score: 4

Explanation: The filing reports significant insider selling by a key executive, which can sometimes be perceived negatively by the market. However, such transactions are often part of pre-planned trading strategies (Rule 10b5-1 plans) and do not necessarily reflect a negative outlook on the company's future. The acquisition of shares via ESPP and the correction of a prior error are neutral to slightly positive administrative details.

Positives

• Acquisition of 4,488 shares under the Employee Stock Purchase Plan on June 30, 2025, indicates continued participation in company equity programs.
• Correction of a previous scrivener's error demonstrates attention to accurate reporting.

Negatives

• Significant sales of common stock totaling 51,900 shares by a key executive.
• A gift of 9,000 shares further reduces direct beneficial ownership.

Risks

• No specific company operational or financial risks are detailed in this Form 4 filing. The filing pertains solely to insider trading activities.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It is a disclosure of past insider transactions.

Industry Context

This filing is a routine disclosure of insider trading activity for Olema Pharmaceuticals, Inc. It does not provide information that allows for a direct analysis of broader industry trends or competitive positioning. Insider transactions are common across all industries and are typically evaluated in the context of a company's overall financial health and market performance.

Comparison to Industry Standards

• This Form 4 filing details specific insider transactions and does not provide data suitable for comparison to global benchmarks, comparable companies, projects, or results within the pharmaceutical industry. The nature of the disclosure is individual-specific rather than company-performance-specific.

Related Party Transactions

• The indirect beneficial ownership through The Myles Family Revocable Inter Vivos Trust and Myles Properties Inc. represents holdings by entities related to the reporting person. However, the reported transactions (sales and gift) are not described as related party transactions in the context of the company itself.

Stakeholder Impact

• Shareholders might interpret the executive's net selling as a potential signal, though it's often routine.
• Employees are not directly impacted by this specific filing, beyond the mention of ESPP participation.
• Customers, suppliers, and creditors are not directly impacted by this insider transaction report.

Key Dates

Keywords

Olema Pharmaceuticals, OLMA, insider trading, Form 4, stock sale, beneficial ownership, executive compensation, equity, common stock, David C. Myles